ArticleOncotarget2018
Vemurafenib in Langerhans cell histiocytosis: report of a pediatric patient and review of the literature.
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04943198 (Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis
Who cites it
19 citing papers in PubMed, 42 citations in OpenAlex.
- Advances in the diagnosis and management of pediatric Langerhans cell histiocytosis and Rosai-Dorfman disease: therapies, biomarkers, and response assessment.Hematology. American Society of Hematology. Education Program · 2025Review
- Molecular Mutations in Histiocytosis: A Comprehensive Survey of Genetic Alterations.Molecular biotechnology · 2025Review
- Targeted Therapy With Vemurafenib in Brazilian Children With Refractory Langerhans Cell Histiocytosis: Two Case Reports and Review of Literature.Cancer reports (Hoboken, N.J.) · 2024Review
- Vemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E-positive LCH.Blood advances · 2023Article
- Patient with treatment resistant peristomal and scalp dermatitis.JAAD case reports · 2023Article
- Gut and liver involvement in pediatric hematolymphoid malignancies.World journal of gastrointestinal oncology · 2022Review
- Limited Utility of Chemotherapy for Pulmonary Langerhans Cell Histiocytosis Due to Unclear Diagnostic Criteria.Cureus · 2022Article
- Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA.International journal of hematology · 2021Article
- Recent advances in the understanding of the molecular pathogenesis and targeted therapy options in Langerhans cell histiocytosis.Blood research · 2021Review
- The Challenges of Crizotinib Treatment in a Child With Anaplastic Large Cell Lymphoma.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2021Article
- Case Report: Early Association of Vemurafenib to Standard Chemotherapy in Multisystem Langerhans Cell Histiocytosis in a Newborn: Taking a Chance for a Better Outcome?Frontiers in oncology · 2021Article
- Nationwide retrospective review of hematopoietic stem cell transplantation in children with refractory Langerhans cell histiocytosis.International journal of hematology · 2020Review
- Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019Observational
- Systemic Histiocytosis (Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Destombes-Rosai-Dorfman Disease): from Oncogenic Mutations to Inflammatory Disorders.Current oncology reports · 2019Review
- Longitudinal assessment of peripheral blood BRAFV600E levels in patients with Langerhans cell histiocytosis.Pediatric research · 2019Article
- Langerhans Cell Histiocytosis: Single Center Experience of 25 Years.Mediterranean journal of hematology and infectious diseases · 2019Article
- Resolved heart tamponade and controlled exophthalmos, facial pain and diabetes insipidus due to Erdheim-Chester disease.BMJ case reports · 2018Article
- Bile Duct Targeting or Preservation: Contrasting Liver Histology in Langerhans Cell Histiocytosis and Disseminated Juvenile Xanthogranuloma.Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology SocietyReview
- [Vemurafenib in refractory langerhans histiocytosis].Developmental period medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Selective BRAF inhibitors such as vemurafenib have become a treatment option in patients with Langerhans cell Histiocytosis (LCH). To date, only 14 patients receiving vemurafenib for LCH have been reported. Although vemurafenib can stabilize the clinical condition of these patients, it does not seem to cure the patients, and it is unknown, when and how to stop vemurafenib treatment. We present a girl with severe multisystem LCH who responded only to vemurafenib. After 8 months of treatment, vemurafenib was tapered and replaced by prednisone and vinblastine, a strategy which has not been described to date. Despite chemotherapy, early relapse occurred, but remission was achieved by re-institution of vemurafenib. Further investigation needs to address the optimal duration of vemurafenib therapy in LCH and whether and which chemotherapeutic regimen may prevent disease relapse after cessation of vemurafenib.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.